Hyperion DeFi, Inc.
HYPD Healthcare Biotechnology
Hyperion DeFi, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $813,500.00, up 1,319.7% from fiscal 2024. In the quarter to June 2026, revenue grew 2,333.3%, EPS grew 140.4%, free cash flow grew 86.8% and total debt rose 12.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow HYPD
Hyperion DeFi, Inc. (HYPD) Altman Z-score
Hyperion DeFi, Inc.'s Altman Z-score for fiscal 2025 is −8.37, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −8.37 | 114.01 |
| FY2024 | −122.38 | (115.45) |
| FY2023 | −6.94 | (8.09) |
| FY2021 | 1.15 | 1.56 |
| FY2020 | −0.41 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.09 | — | 0.11 | |
| Retained earnings / total assets | (4.65) | — | −6.51 | |
| EBIT / total assets | (0.90) | — | −2.98 | |
| Market value of equity / total liabilities | 1.66 | — | 1.00 | |
| Sales / total assets | 0.02 | — | 0.02 | |
| Altman Z-score | Distress zone | −8.37 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −16.62 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| ACET Adicet Bio, Inc. compare | 5.0× |
| IBIO iBio, Inc. compare | 2.8× |
| ELTX Elicio Therapeutics, Inc. compare | 0.1× |
| HOWL Werewolf Therapeutics, Inc. compare | −4.8× |
| CRBU Caribou Biosciences, Inc. compare | −5.0× |
| HYPD Hyperion DeFi, Inc. | −8.4× |
| MREO Mereo BioPharma Group plc - Sponsored ADR compare | −9.1× |
| KLRS Kalaris Therapeutics Inc. compare | — |
| LONA LeonaBio, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets